Company
LON:BVX
BiVictriX Therapeutics PLC is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities. The company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni ® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni ® fingerprints", on tumour cells, which are largely absent from healthy cells.
42 stories · page 3 of 3
"Oliver's long career in cancer research, most recently leading teams in antibody-based therapeutics development and manufacturing, will be invaluable as we build our internal capabilities," said CEO Tiffany Thorn
Pioneering a "highly selective" approach to treating the disease Looks for a cancer fingerprint to target the illness Initially developing a treatment for acute myeloid leukaemia
